Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow: 2014-2025

Historic Net Cash Flow for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $66.5 million.

  • Viking Therapeutics' Net Cash Flow rose 929.28% to $66.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 280.10%. This contributed to the annual value of -$28.7 million for FY2024, which is 251.70% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Net Cash Flow is $66.5 million, which was up 1,742.84% from -$4.0 million recorded in Q2 2025.
  • Viking Therapeutics' Net Cash Flow's 5-year high stood at $140.1 million during Q1 2024, with a 5-year trough of -$151.7 million in Q2 2024.
  • For the 3-year period, Viking Therapeutics' Net Cash Flow averaged around $5.8 million, with its median value being $6.5 million (2024).
  • In the last 5 years, Viking Therapeutics' Net Cash Flow soared by 1,195.85% in 2023 and then slumped by 396.46% in 2024.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Net Cash Flow stood at $15.1 million in 2021, then plummeted by 53.11% to $7.1 million in 2022, then soared by 158.10% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then surged by 929.28% to $66.5 million in 2025.
  • Its Net Cash Flow was $66.5 million in Q3 2025, compared to -$4.0 million in Q2 2025 and $11.3 million in Q1 2025.